title: Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
abstract: The discovery of anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) in 2007 and the approval of crizotinib for the treatment of advanced ALK-rearranged NSCLC in 2011 represents a landmark in the development of targeted oncology therapy. The approval of crizotinib was accompanied simultaneously by the approval of the Vysis (Abbott Molecular) break-apart fluorescence in situ hybridization (FISH) test as the companion diagnostic (CDx) test to detect ALK rearrangement. Pfizer, the manufacturer of crizotinib, sponsored the screening of thousands of patients and the standardization of the ALK FISH test as part of the approval process for crizotinib, a first in class ALK inhibitor. Many pharmaceutical companies are now using the Food and Drug Administration (FDA)-approved ALK FISH assay to enroll patients onto trials for their own respective ALK inhibitors. In essence they are "piggybacking" on the FDA-approved ALK FISH assay without having to pay for the development of a CDx, nor screening for ALK-rearranged NSCLC patients in the protocols because screening for ALK rearrangement is now the standard of care in NSCLC after the approval of crizotinib. Since 2007, rearrangement in more receptor tyrosine kinases (RTKs) such as ROS1, RET, AXL, PDGFR-α, and NTRK1 have been discovered in NSCLC but the incidence of each subtype of RTK-rearranged NSCLC is quite rare. Crizotinib has now demonstrated significant clinical activity in ROS1-rearranged NSCLC patients. Whether crizotinib will gain official FDA approval for use in ROS1-rearranged NSCLC, on the other hand, remains unclear as there is no test for ROS1-rearrangement currently being developed to support US FDA approval as a CDx. This may be due in part to the fact that the full cost associated with the development of a pre-market approved-approved CDx must be borne by the company seeking the first drug approval in a new indication. Given the low incidence of ROS1-rearrangement in NSCLC, and the availability of crizotinib in most countries, a more cost-effective way is for crizotinib to gain compendium listing for ROS1-rearranged NSCLC in treatment guidelines. However, without a formal indication from the FDA, a drug cannot be marketed for off label use, it is unlikely that payers public or private will routinely pay for molecular testing for ROS1-rearrangement in NSCLC let alone reimburse off label use of crizotinib. Similarly, several marketed tyrosine kinase inhibitors (TKIs) in the US (sorafenib, sunitinib, vandetanib, cabozantinib, regorafenib) are potent RET inhibitors in vitro. It does not make sense for any one pharmaceutical company to shoulder the full cost of developing a particular CDx for RET-rearranged NSCLC where, once approved, it may be used by other pharmaceutical companies to gain addition labeling approval for their own RET inhibitors. Thus, the requirement by the US FDA that a specific CDx have to be co-developed and standardized for each of the molecular subtype of NSCLC as part of the drug approval process, while prudent, may have the un-intended consequence of deterring clinical development of these TKIs in these very rare molecular subsets of NSCLC. While we all march to the drumbeat of precision cancer medicine, the stringent requirement of co-development CDx for each molecular subtype of solid tumor may inadvertently make this goal substantially more difficult to achieve.
authors.affiliation: Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine , Orange, CA , USA.
authors.forename: Sai-Hong Ignatius
authors.initials: SH
authors.lastname: Ou
authors.affiliation: National University Health System and Cancer Science Institute of Singapore , Singapore.
authors.forename: Ross A
authors.initials: RA
authors.lastname: Soo
authors.affiliation: Aichi Medical University School of Medicine , Nagakute , Japan.
authors.forename: Akihito
authors.initials: A
authors.lastname: Kubo
authors.affiliation: National Hospital Organization Kinki-Chuo Chest Medical Center , Sakai City , Japan.
authors.forename: Tomoya
authors.initials: T
authors.lastname: Kawaguchi
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea.
authors.forename: Myung-Ju
authors.initials: MJ
authors.lastname: Ahn
keywords: ALK-rearranged NSCLC; RET-rearranged NSCLC; ROS1-rearranged NSCLC; companion diagnostics; fluorescence in situ hybridization; immunohistochemistry; next generation sequencing; reverse transcription-polymerase chain reaction
references.citation: Oncologist. 2013;18(7):865-75
references.pmid: 23814043
references.citation: J Thorac Oncol. 2012 Sep;7(9):e14-6
references.pmid: 22895149
references.citation: Cancer Res. 2002 Dec 15;62(24):7284-90
references.pmid: 12499271
references.citation: Nature. 2001 May 17;411(6835):355-65
references.pmid: 11357143
references.citation: Mol Cancer Res. 2014 Jan;12(1):111-8
references.pmid: 24296758
references.citation: Cell. 1985 Sep;42(2):581-8
references.pmid: 2992805
references.citation: Nature. 1986 Feb 27-Mar 5;319(6056):743-8
references.pmid: 2869410
references.citation: Genes Chromosomes Cancer. 2003 May;37(1):58-71
references.pmid: 12661006
references.citation: J Thorac Oncol. 2014 Jan;9(1):18-25
references.pmid: 24346090
references.citation: J Clin Oncol. 2012 Dec 10;30(35):4352-9
references.pmid: 23150706
references.citation: Thyroid. 2013 Dec;23(12):1569-77
references.pmid: 23705946
references.citation: Mol Cancer Ther. 2009 Jul;8(7):1818-27
references.pmid: 19509272
references.citation: Cancer Lett. 2013 Oct 28;340(1):97-103
references.pmid: 23856031
references.citation: J Thorac Oncol. 2011 Jan;6(1):21-7
references.pmid: 21107285
references.citation: Leukemia. 2008 Nov;22(11):1999-2010
references.pmid: 18843283
references.citation: Am J Surg Pathol. 2013 Sep;37(9):1441-9
references.pmid: 23887156
references.citation: Cancer Discov. 2013 Jun;3(6):630-5
references.pmid: 23533264
references.citation: Nat Rev Drug Discov. 2013 Oct;12(10):743-55
references.pmid: 24008432
references.citation: Genome Res. 2012 Nov;22(11):2109-19
references.pmid: 22975805
references.citation: Nat Genet. 2004 Apr;36(4):331-4
references.pmid: 15054488
references.citation: Nat Med. 2013 Nov;19(11):1469-1472
references.pmid: 24162815
references.citation: Haematologica. 2007 Sep;92(9):1173-9
references.pmid: 17666373
references.citation: Leukemia. 2012 Nov;26(11):2384-9
references.pmid: 22513837
references.citation: Mol Cancer Ther. 2011 Oct;10(10):1763-73
references.pmid: 21933973
references.citation: Cell. 2007 Dec 14;131(6):1190-203
references.pmid: 18083107
references.citation: Ann Oncol. 2013 Oct;24(10):2589-2593
references.pmid: 23904459
references.citation: Clin Cancer Res. 2012 Sep 1;18(17):4682-90
references.pmid: 22912387
references.citation: Mol Cell Endocrinol. 2013 Sep 5;377(1-2):1-6
references.pmid: 23811235
references.citation: Oncologist. 2012;17(11):1351-75
references.pmid: 22989574
references.citation: Eur J Endocrinol. 2006 Nov;155(5):645-53
references.pmid: 17062879
references.citation: J Natl Cancer Inst. 2006 Mar 1;98(5):326-34
references.pmid: 16507829
references.citation: Mol Cell Biol. 1991 Oct;11(10):5016-31
references.pmid: 1656220
references.citation: Cancer. 2013 May 1;119(9):1627-35
references.pmid: 23400546
references.citation: Nat Rev Cancer. 2013 Nov;13(11):772-87
references.pmid: 24132104
references.citation: Mol Cell Endocrinol. 2010 May 28;321(1):44-9
references.pmid: 19883730
references.citation: Int J Cancer. 2011 Jul 1;129(1):245-55
references.pmid: 21170960
references.citation: N Engl J Med. 2013 Jun 20;368(25):2385-94
references.pmid: 23724913
references.citation: Nat Rev Drug Discov. 2013 Jul;12(7):507-25
references.pmid: 23977697
references.citation: Invest New Drugs. 2012 Dec;30(6):2334-43
references.pmid: 22160853
references.citation: Expert Rev Anticancer Ther. 2012 Apr;12(4):447-56
references.pmid: 22500682
references.citation: J Thorac Oncol. 2011 Mar;6(3):466-72
references.pmid: 21258247